Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy

Abstract

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy, HELIYON, https://doi.org/10.1016/j.heliyon.2021.e07916. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Prognostic and predictive impact of neutrophil‐to‐lymphocyte ratio and HLA‐I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy

“…We observed a significantly shorter OS in patients with HLA‐I homozygosity, consistent with the findings by Chowell et al in patients with melanoma 23 . In addition, we demonstrated an inferior PFS, ORR and DCR in patients with HLA‐I homozygosity, which has not been comprehensively analyzed and reported in previous studies 23–26 . Supertype analysis found that supertype B27 might have an impact on OS without significant interactions with other clinicopathological features, suggesting the peptides presented by HLA‐I B27 might be important in ESCC, and this hypothesis warrants further verification.…”

“…23 In addition, we demonstrated an inferior PFS, ORR and DCR in patients with HLA-I homozygosity, which has not been comprehensively analyzed and reported in previous studies. [23][24][25][26] Supertype analysis found that supertype B27 might have an impact on OS without significant interactions with other clinicopathological features, suggesting the peptides presented by HLA-I B27 might be important in ESCC, and this hypothesis warrants further verification. Also, HLA-I homozygosity led to worse clinical outcomes regardless of PD-L1 status, while the differences were especially remarkable in the subgroup with PD-L1 TPS ≥10%.…”

“…It has been found that HLA-I heterozygosity at all loci (A, B, and C) is associated with improved OS than HLA-I homozygosity in at least one HLA locus in patients with melanoma or NSCLC, supporting the speculation that a more diverse HLA class I repertoire would lead to a better T lymphocytebased antitumor immune response. [23][24][25][26] However, the relationship between HLA-I genotyping and clinical outcomes in ICI-treated ESCC patients has not previously been investigated.…”